Andrew Holden (New Zealand; CX Executive Board Member) discusses some of the main features of the upcoming Peripheral Proximal session at CX 2021 as well as his Podium 1st presentation–Five-year meta-analysis including mortality update with FDA-approved RCTs of paclitaxel devices.
You can register for CX 2021 here.
